Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/EPAR/columvihttps://www.ema.europa.eu/en/medicines/human/EPAR/columvi
Retrieved on: 
Vendredi, janvier 5, 2024
Information
Tags: 
Patient, Medical Subject Headings, Marketing, Febrile neutropenia, Agency, INN, Fever, Immune system, Risk, Infection, Diffusion, Allergy, DLBCL, ATC, Bone marrow, Cytokine release syndrome, CD20, Platelet, International, Headache, Disease, Neutropenia, Blood, Language, Pleural effusion, Cancer, B-cell lymphoma, Thrombocytopenia, Neutrophil, Rituximab, COVID-19, European Medicines Agency, Select, Bacteria, Anatomy, Anemia, IIA, Sepsis, CD3, Rash, Medical device
Geotags: 
RARE, EU
Résumé
Key Points: 


Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Copyright: 
2024 European Medicines Agency. All Rights Reserved.